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A B S T R A C T
Objective. Congenital cardiac defects represent the most common group of birth defects, affecting an estimated six
per 1000 births. Genetic characterization of patients and families with cardiac defects has identified a number of
genes required for heart development. Yet, despite the rapid pace of these advances, mutations affecting known genes
still account for only a small fraction of congenital heart defects suggesting that many more genes and developmental
mechanisms remain to be identified.
Design. In this study, we reviewed 1694 described cases of patients with cardiac defects who were determined to
have a significant chromosomal imbalance (a deletion or duplication). The cases were collected from publicly
available databases (DECIPHER, ISCA, and CHDWiki) and from recent publications. An additional 68 nonredun-
dant cases were included from the University of Michigan. Cases with multiple chromosomal or whole chromosome
defects (trisomy 13, 18, 21) were excluded, and cases with overlapping deletions and/or insertions were grouped to
identify regions potentially involved in heart development.
Results. Seventy-nine chromosomal regions were identified in which 5 or more patients had overlapping imbal-
ances. Regions of overlap were used to determine minimal critical domains most likely to contain genes or regulatory
elements involved in heart development. This approach was used to refine the critical regions responsible for cardiac
defects associated with chromosomal imbalances involving 1q24.2, 2q31.1, 15q26.3, and 22q11.2.
Conclusions. The pattern of chromosomal imbalances in patients with congenital cardiac defects suggests that many
loci may be involved in normal heart development, some with very strong and direct effects and others with less
direct effects. Chromosomal duplication/deletion mapping will provide an important roadmap for genome-wide
sequencing and genetic mapping strategies to identify novel genes critical for heart development.
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Introduction
The high morbidity and mortality associatedwith severe congenital cardiac defects has
stimulated the search for new strategies to
decrease their frequency, reduce their severity and
improve their treatment. While advances in surgi-
cal and medical care have substantially improved
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patient outcomes, recent studies suggest morbidity
and mortality remains high for some of the most
severe defects and that further improvements in
outcomes may depend on the development of new
therapeutic approaches.1,2 However, our ability to
reduce the incidence or severity of heart defects is
limited by an incomplete understanding of their
causes.3 Previous studies have identified genes
responsible for some types of congenital heart
defects (CHDs).4,5 To date, the identified genes
appear to account for only a small percentage of
the observed cases. This suggests that the patho-
physiology of congenital heart disease is quite
complex, potentially involving a large number of
genes and genetic defects with variable levels of
expressivity. Similar to other disorders demon-
strating a complex pattern of inheritance, CHDs
may often depend on the concurrent inheritance
of multiple predisposing genetic factors that inter-
act with epigenetic or environmental influences to
result in impaired structural development.6 The
current challenge therefore is to identify such pre-
disposing genetic factors that contribute to heart
defects to aid development of new therapeutic
strategies.
To meet this challenge, a number of approaches
have been used to identify genes responsible for
cardiac defects. In addition to the characterization
of rare families with clear patterns of inheritance,
targeted sequencing of genes determined to be
potentially involved in heart development, either
based on functional analysis in animal models or
mapping chromosomal deletions/duplications in
patients, has been successful in identifying caus-
ative mutations in patients with CHD.3 In patients
without significant chromosomal imbalances or
clear familial inheritance, whole exome sequenc-
ing strategies have been utilized to identify
disease-causing mutations in known or novel heart
development genes.7 Unfortunately, these nondi-
rected sequencing strategies identify hundreds of
novel genetic variants of unknown significance for
each patient. Prioritizing sequence variants for
further evaluation depends on (1) the identifica-
tion of potentially pathogenic mutations using
bioinformatics; (2) the identification and charac-
terization of genes expressed in the tissues that
contribute to cardiac development; and (3) the
characterization of genetic and genomic abnor-
malities in other patients with congenital cardiac
defects.
In this study, we sought to develop a roadmap
for the prioritization of novel genetic variants in
patients with heart defects by identifying genomic
regions associated with congenital heart disease
based on the mapping of chromosomal imbal-
ances. Chromosomal imbalances occur approxi-
mately in 8–13% of patients with CHDs8 and may
represent important opportunities to localize and
identify genes potentially involved in human
cardiac development and the genesis of CHDs. In
our review of publicly available databases and pub-
lications, we identified 1694 patients with a chro-
mosomal imbalance (duplication or deletion) and
congenital cardiac malformations. In addition, we
identified 68 patients from our own institution.
Patients with overlapping genomic abnormalities
were grouped to identify minimal critical regions
encompassing potential candidate genes involved
in human cardiac development. We identified 79
chromosomal regions in which duplications or
deletions have resulted in CHDs in five or more
patients. Several of the regions identified have
been noted previously to be involved in cardiac
development including recurring deletions on
chromosomes 7 and 22 (Williams and DiGeorge
syndromes), and chromosomes 5 and 8 (involving
the cardiac transcription factors NKX2-5 and
GATA4). In addition, multiple sets of overlapping
deletions and/or duplications were identified that
may represent the locations of novel genes
involved in cardiac development.
Methods
Database Search
The following three sources were used to identify
patients for analysis: (1) the DECIPHER database
(an international database containing genomic and
phenotypic information on patients from over 150
centers in 29 countries)9; (2) the International Stan-
dards for Cytogenomic Arrays (ISCA) consortium;
and (3) the Benchv3.3 beta database. For each data-
base, a series of search terms were used to identify
cases involving CHDs. For the DECIPHER data-
base, the search term “heart” was used to identify
patients with CHDs. For the ISCA database,
the following search terms were used: atrial
septal defect (ASD), AV canal defect, coarctation of
the aorta (CoA), hypoplastic left heart, tetralogy
of Fallot (TOF), ventricular septal defect (VSD),
and heart. The Benchv3.3 database included a
linked site for identified cases with CHDs (http://
homes.esat.kuleuven.be/∼bioiuser/chdwiki/index
.php/CHD:Reports).10
Expansion of the Database Using Published Data
In addition, data were pooled from four recent
publications examining the contribution of copy
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number variation to the pathogenesis of
CHDs.11–14 The formats used for copy number
variant (CNV) identification and verification are
described in each publication. Only those cases in
which a single or primary CNV could be identified
were included in the database for this study. Cases
with more than one CNV were included if the
“secondary” CNVs were known to be common in
the general population and were less than 100 kb
in size. Patients with identical recorded pheno-
types and identical genomic imbalances repre-
sented in multiple databases and/or publications
were deemed to be the same patient and were
recorded only once.
Mapping of CNVs
For each case, the deleted or duplicated intervals
had been previously mapped to the human
genome reference sequence using the NCBI36/
hg18 or GRCh37/hg19 genome builds. All
sequences were converted to the numbering of
the GRCh37/hg19 genome build using the Lift-
Over program (http://genome.ucsc.edu/cgi-bin/
hgLiftOver). For those sequences not successfully
converted by the LiftOver program, approximate
boundaries were determined using nearby genes
and markers in the NCBI36/hg18 genome build
and locating the corresponding markers/genes on
the GRCh37/hg19 genome map. As those bound-
aries are less definite, they are represented in red
in the composite database.
Grouping of Cases with Overlapping CNVs
There are many approaches to group the observed
cases. The full database can be retrieved and
resorted based on specific interests or scientific
questions. We have presented one approach, but
there are many alternatives. To identify regions of
overlap, the cases were sorted by chromosome and
then sequentially by proximal and distal boundary
location (using the GRCh37/hg19 genome build).
Eighty-one regions with at least five cases of over-
lapping duplications and/or deletions were identi-
fied by visual inspection. Proximal and distal
“secondary” boundaries were determined based on
the presence of at least one case with a breakpoint
internal to the proposed boundary. This was
done to ensure that an important candidate
gene would not be excluded based on a single
breakpoint in an individual case. The candidate
region was identified using the UCSC Genome
Browser on Human Feb. 2009 (GRCh37/
hg19) Assembly (http://genome.ucsc.edu/cgi-bin/
hgGateway?hgsid=353279827). A list of genes in
the region was recorded and examined for candi-
date genes known or suspected to have a role in
human heart development. If a definite candidate
was present, it was used to organize the overlap-
ping cases in that all cases involving that locus
were grouped prior to grouping the cases near but
not involving the known cardiac gene. After
regrouping based on candidate genes, a total of 79
candidate regions affected in five or more patients
were identified.
Estimate of Percentage of Chromosomal Imbalances
Associated with Congenital Cardiac Defects
For each of the 79 regions affected (included in a
deletion or duplication) in five or more CHD
patients, a candidate gene within the minimal
region was identified and used to determine the
copy number of that candidate region (recogniz-
ing that the selected gene may or may not be the
one responsible for the observed cardiac defects).
To determine if the incidence of cardiac defects
associated with the gain or loss of that locus was in
excess of what would be expected from a normal
control population, we compared the rate of gain
or loss of each locus in a population of patients
referred to Signature Genomics for microarray
testing with a diagnosis of a known cardiac defects
(n = 1964) and in a control population without
known heart disease (n = 8329). The analysis was
restricted to this dataset as the other datasets were
more subject to ascertainment bias making an
accurate estimate of the denominator less reliable.
The examined cases are a subset of the prenatal
and postnatal cases submitted to Signature
Genomics for clinical microarray-based compara-
tive genomic hybridization from 2004 to 2013
(n = 58 980) and were tested using a variety of
platforms, including targeted and whole-genome
bacterial artificial chromosome arrays and whole-
genome oligonucleotide-based arrays. This
dataset includes all cases described in Cooper
et al.13 For each candidate region, the percentage
of deletions and duplications that were associated
with a reported cardiac defect was recorded. To
determine if the observed difference between the
CHD and control populations were statistically
significant, a Wilcoxon signed rank test was used.
University of Michigan Patients
Retrospective chart review was approved by
the Institutional Review Board for Human
Subject Research at the University of Michigan.
Chromosomal microarray analyses were con-
ducted in the Michigan Medical Genetics Labo-
Congenit Heart Dis. 2015;10:193–208
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ratories at the University of Michigan using two
oligonucleotide-based array platforms with whole
genome coverage: a custom-designed EMArray
Cyto6000 chip (Emory Genetics Laboratory,
Decatur, GA, USA), implemented on the Agilent
44 K platform (Agilent Technologies, Inc., Santa
Clara, CA, USA),15 and the Illumina CytoSNP12
array. The procedures for array comparative
genomic hybridization were performed according
to the manufacturer’s protocols as described in
Quinonez et al.16 The HumanCytoSNP-12 Bead-
Chip assay (Illumina, San Diego, CA, USA),
which targets the entire genome using 300 K
probes, was performed according to the Infinium
HD Ultra protocol provided by the manufacturer
(Illumina). Briefly, 200 ng of genomic DNA was
used for whole-genome amplification at 37°C for
20–24 hours. The amplified DNA was enzymati-
cally fragmented, purified, loaded on the
HumanCytoSNP-12 BeadChip, and allowed to
hybridize at 48°C for 16–24 hours. Subsequently,
the hybridizing DNA on the BeadChip was
labeled by enzymatic single base extension and
incorporated nucleotides were detected using
fluorescently labeled antibodies. Stained Bead-
Chips were scanned using a HiScan (Illumina).
Data were generated with GenomeStudio (Illu-
mina) and analyzed with Nexus Copy Number
software version 6 (BioDiscovery, Hawthorne,
CA, USA).
Results
The 1694 patients with congenital cardiac defects
and chromosomal imbalances were identified in
the databases and publications examined in this
study, and 68 patients with congenital cardiac
defects and chromosomal imbalances were
included from our institution. The deletion or
duplication was assigned to a specific chromo-
somal segment based on the available mapping
data. The set of genes affected by the chromo-
somal imbalances were retrieved from the data-
bases and used to develop a minimum overlapping
set of genes for each locus. We identified 79
potential genetic loci that were involved in a
minimum of five overlapping deletions or duplica-
tions (see Table 1 and Supporting Information
Table S1).
Distribution of Insertions/Deletions Leading to CHDs
Chromosomal deletions and duplications associ-
ated with CHDs were not randomly distributed
throughout the genome. There was clustering of
CHD-associated genomic imbalances at particular
chromosomal locations, including those involved
in known cardiac syndromes and at the telomeres.
Telomeric and subtelomeric deletions and dupli-
cations associated with congenital cardiac defects
involved regions on distal chromosomes 1p, 1q,
2q, 3p, 3q, 4p, 5p, 5q, 6p, 8p, 9p, 9q, 10q, 11p, 11q,
12p, 14q, 15q, 16p, 16q, 17p, 17q, 18q, 19p, and
20q.
Chromosomal Duplication/Deletions Affecting Loci
Known to Have a Role in CHD
As would be expected, there were a number of
patients with chromosomal imbalances affecting
regions previously determined to have role in
heart development. Deletions affecting TBX1
(DiGeorge syndrome) and elastin (Williams syn-
drome) were identified in 36 and 18 patients,
respectively. These deletions may be relatively
underrepresented in the databases as they have
been well described and there is little incentive to
catalogue additional patients with these deletions.
Deletions affecting NKX2-5 and GATA4 were
identified in 7 and 38 patients, respectively. Five
of the patients with NKX2-5 deletions were
described as having ASDs with or without other
cardiac abnormalities including atrioventricular
block in three patients. There was a broad range of
defects in patients haplosufficient for GATA4 with
the majority being described as atrial or ventricu-
lar septal defects and relatively frequently, in 12/38
patients, complete atrioventricular septal defects.
This is consistent with a recent finding that copy
number variants affecting GATA4 were overrepre-
sented in patients with atrioventricular septal
defect (AVSD).12
Mutations in transforming growth factor-beta
(TGFβ)-activated kinase (TAB2) have previously
been noted in patients with CHDs.17 Deletions of
TAB2 were noted in 11 patients and a duplication
in one patient with a range of cardiac defects
including ASDs and VSDs, as well as aortic and
pulmonary stenosis. Several other genes previ-
ously noted to have deleterious mutations in
patients with CHDs were affected by chromo-
somal imbalances in at least five patients including
CRELD1, CHD7, CREBBP, EHMT1, HAND2,
and NOTCH1 (Table 1).
Chromosomal Insertions/Deletions Affecting Loci
Suspected to Have a Role in CHD
Other chromosomal imbalances involved loci that
contain genes that have been demonstrated in
animal models to be involved in heart develop-
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ment but have not previously been implicated in
causing human CHDs. These included imbalances
involving ETS1, HES4, MEF2A, MTHFR, TBX2,
or TBX6 in five or more patients (Table 1).
Relative Risk of Congenital Cardiac Defects for Each
Candidate Region
One of the major limitations of relying on data-
base reporting for this type of analysis is the inabil-
ity to assess risk of developing a cardiovascular
abnormality if a particular gene or genetic region
is involved in a chromosomal imbalance. To
address this, we reviewed a large dataset of patients
tested at a clinical microarray laboratory (Signa-
ture Genomics Inc., Spokane, WA, USA), which
includes those reported by Cooper et al.13 From
that dataset, a rough estimate could be obtained of
the relative risk of a CHD when a specific gene
was involved in a chromosomal imbalance by com-
paring the gain or loss of that gene in a population
of patients with known or suspected cardiac
defects referred for copy number analysis com-
Table 1. Regions with Chromosomal Imbalances Noted in Five or More Patients with Congenital Heart Defects
Chrom Location Gene Heart Defects Chrom Location Gene Heart Defects
1 934 342 HES4 ASD; CM; VSD 9 139 388 896 NOTCH1 CoA; VSD; ASD; TOF
1 8 420 172 RERE VSD; PS; AVSD 9 140 513 444 EHMT1 VSD; ASD; TOF
1 104 159 999 AMY2A VSD; ASD;TOF 10 47 658 233 ANTXRL TOF; PA; VSD
1 147 228 332 GJA5 TOF; AS; ASD; SV; TGA;
CoA; VSD
10 88 516 396 BMPR1A AVSD; ASD
1 170 633 313 PRRX1 VSD 10 117 061 365 ATRNL1 PDA; VSD; TOF
1 245 912 642 SMYD3 VSD; PDA; TOF 10 135 340 867 CYP2E1 TOF; VSD
2 49 210 237 FSHR TOF; HEART 11 50 368 318 LOC646813 PS; ASD
2 108 459 465 RGPD4 ASD; TOF; CoA 11 128 328 656 ETS1 VSD; ASD; PDA
2 110 935 964 NPHP1 TOF; HLHS; CoA 11 134 598 320 NKX6-2 TOF; CAT; HEART
2 175 212 878 CIR1 ASD, VSD, PDA, DORV 12 34 175 216 ALG10 TOF; PS; AVSD
3 1 134 620 CNTN6 AVSD; TOF 12 60 083 118 SLC16A7 ASD; PS; CoA; HLHS
3 8 775 486 CRELD1 ASD; AVSD 14 20 167 619 LOC100506393 TOF; PA; VSD; ASD
3 196 466 728 PAK2 ASD; PS; PDA 15 20 737 094 GOLGA6L6 TGA; ASD
4 53 227 ZNF595 PS; ASD; VSD; HLHS 15 22 051 853 POTEB TOF; VSD; ASD
4 1 005 760 FGFRL1 ASD; VSD; TGA 15 22 546 565 REREP3 TOF; VSD; ASD; TGA
4 89 178 761 PPM1K ASD; TOF 15 22 833 395 CYFIP1 CoA; VSD; ASD; TOF; CAT;
TAPVR
4 91 048 684 CCSER1 ASD; PDA; CoA 15 32 322 686 CHRNA7 ASD; PDA; PS; HET
4 135 117 489 PABPC4L TOF; TGA; PDA 15 55 495 164 RAB27A CoA; AS; HLHS
4 174 447 652 HAND2 ASD; VSD; PS; TOF 15 100 106 133 MEF2A HLHS; VSD; ASD; AVSD; PS
5 659 977 TPPP HEART; ASD; TOF 16 3 775 056 CREBBP ASD; PFO; PDA
5 37 812 779 GDNF PDA; ASD 16 15 806 751 MYH11 ASD; VSD
5 70 330 951 GTF2H2 HEART; TOF; ASD 16 30 097 115 TBX6 ASD; VSD; CoA
5 172 659 107 NKX2-5 ASD; AVB; EBS 16 86 544 133 FOXC2 HLHS; IAA; AVSD; PA; LSVC
5 176 513 921 FGFR4 PDA; VSD 17 19 281 774 MAPK7 ASD; VSD; HLHS; HEART
6 292 101 DUSP22 ASD 17 17 584 787 AATF HEART; ASD; AVSD
6 149 639 436 TAB2 ASD, VSD, PS, AS, CM 17 44 107 282 KANSL1 ASD; VSD; PDA; PS
6 161 768 590 PARK2 TOF; HLHS; AS 17 59 477 257 TBX2 ASD; PDA; BAV
6 168 707 584 DACT2 TOF; ASD; VSD 18 580 369 CETN1 AS; TOF; HEART
7 64 864 053 ZNF92 VSD; TOF; PS 20 13 976 146 MACROD2 TGA; ASD
7 73 442 427 ELN SVPS; SVAS; VSD 21 28 208 606 ADAMTS1 AVSD; PS; AS
7 88 388 753 ZNF804B CoA; TOF; SV 21 36 160 098 RUNX1 AVSD; PA; TGA
7 110 303 106 IMMP2L TOF; TA;PS 22 19 744 226 TBX1 CAT; TOF; VSD; CoA; DORV
7 132 469 623 CHCHD3 AS; CoA; VSD 22 21 353 326 CRKL TOF; ASD; VSD
7 143 970 523 ARHGEF34P TGA; TOF; PA 22 22 113 947 MAPK1 CAT; TA; TOF
8 385 585 FBXO25 HEART; VSD 22 22 311 403 TOP3B TOF; AS
8 7 272 385 DEFB4B HEART; VSD; ASD; AVSD 22 25 747 385 LRP5L TOF; ASD
8 11 561 717 GATA4 TOF; AVSD; VSD; BSVC 22 29 999 545 NF2 PS; VSD
8 61 591 324 CHD7 ASD, AVSD, IAA X 585 079 SHOX CoA; AS
9 214 865 DOCK8 TOF; ASD; VSD X 7 866 804 PNPLA4 VSD; HEART; BAV
9 504 695 KANK1 TOF; PS
Shown are the chromosome (Chrom) and approximate genetic location (Genome Reference Consortium Human Build 37 [GRCh37/hg19]), a gene within the
minimal region of overlap and the observed spectrum of heart defects. Genes that have been previously identified with coding sequence mutations in patients with
congenital cardiac defects are in red text; those determined to have a role in heart development based on an animal model (but without identified sequence variants
in patients with heart defects) are in blue. Each locus spans multiple genes, and the location and listed gene are only intended to provide a landmark for the
candidate interval. The boundaries of the critical region can be derived from the individual cases presented in Supporting Information Table S1. Heart defects listed
include coarctation of the aorta (CoA), interrupted aortic arch (IAA), hypoplastic left heart syndrome (HLHS), atrial and ventricular septal defects (ASDs and VSDs),
atrioventricular septal defect (AVSD), tetralogy of FALLOT (TOF), double outlet right ventricle (DORV), bicuspid aortic valve (BAV), truncus arteriosus (CAT), situs
inversus (SI), heterotaxy (HET), supravalvar aortic and pulmonary stenosis (SVAS and SVPS), aortic stenosis or insufficiency (AS or AI), pulmonary stenosis or
insufficiency (PS or PI), tricuspid stenosis or regurgitation (TS or TR), mitral stenosis or regurgitation (MS or MR), total or partial anomalous venous return (TAPVR
or PAPVR), tricuspid atresia (TA), pulmonary atresia (PA), patent ductus arteriosus (PDA), left or bilateral superior vena cava (LSVC or BSVC), cardiomyopathy
and left ventricular noncompaction (CM and LVNC), and Ebstein’s anomaly (EBS). If the heart defect was not described, then “HEART” is listed.
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pared with a healthy control population. This
analysis was performed for the 79 loci noted to be
involved in chromosomal copy number variations
in at least five patients.
For 66 of the 79 loci involved in chromosomal
imbalances in five or more cases with CHD, the
incidence of deletions and duplications in a control
population of 8329 individuals without known
CHDs was available. A total of 36 of these 66 loci
were noted to have a significantly increased risk
of CHDs compared with control when involved
in a chromosomal duplication and/or deletion
(Table 2). As noted above, 11 of the loci (including
loci containing the ELN, HAND2, GATA4, GJA5,
and TBX1) demonstrated significant elevations in
CHD risk when the locus was duplicated and when
it was deleted while the remaining 25 only achieved
significance for a duplication or a deletion. For
many loci, there were not enough occurrences of a
duplication or deletion to calculate a meaningful
statistic for that type of imbalance. Given the rarity
of chromosomal loss or gain in the healthy popu-
lation, it was difficult to exclude any of the identi-
fied loci as definitively not being associated with an
increased risk of CHD with a gain or a loss.
However, frequent chromosomal imbalances of
loci on chromosome 7q31.1 (which includes
IMMPL2) and on chromosome 6q26 (which
includes PARK2) in the control population makes
their involvement in CHD pathogenesis unlikely.
Furthermore, several loci were only reported from
a single database raising the possibility that the
assignment of a chromosomal imbalance was an
artifact of the testing format. In fact, this single
data source artifact might account for six of the 12
loci for which imbalances were noted in five or
more CHD cases, but no incidence data were avail-
able. These loci are also unlikely to be involved in
CHD pathogenesis.
Other genes previously implicated in CHD
pathogenesis, including the NOTCH1, TAB2, and
CHD7 genes, were more frequently involved in
chromosomal imbalances in patients with CHD
than in controls. In general, genes determined to
be important for cardiac development were not
commonly involved in chromosomal imbalances
and when imbalances do occur they are com-
monly associated with congenital cardiac defects.
Therefore, a complementary approach to assess-
ing risk of CHD is to estimate penetrance of
CHD in individuals with a gain or loss of a spe-
cific gene or locus (Table 3). Deletions of GATA4
were noted to be associated with congenital
cardiac defects in 9/21 patients in the Signature
dataset13 and 11/11 patients in the DECIPHER
database. Interestingly, deletions involving TBX1
resulted in reported cardiac abnormalities in 27%
of the patients in the Signature dataset and in
40% of the patients in the DECIPHER database.
This is comparable with the previously reported
rate of cardiovascular abnormalities (approxi-
mately 25%) in patients with DiGeorge syn-
drome.18 Chromosomal imbalances involving
NOTCH1, which has been demonstrated to be
responsible for cardiac defects in some families,19
are also associated with an elevated risk of CHDs.
The incidence of reported cardiac defects in
patients with deletions of NOTCH1 is approxi-
mately 50% based on the datasets from DECI-
PHER and from the Signature database.13
Therefore, the frequency with which a chromo-
somal deletion involving a gene known to be
involved in heart development results in a con-
genital cardiac defect varies and the penetrance
is usually incomplete suggesting that other
factors, either genetic or environmental, may be
important for chromosomal imbalances to cause
clinically significant congenital heart disease.
Refinement of Candidate Loci for CHD
How the data in the databases can be used to
restrict the candidate regions for novel genes
involved in human heart development and the
pathogenesis of CHD is demonstrated with the
following examples.
Table 2. Incidence of Reported Congenital Heart Defects
in Patients with Chromosomal Imbalances Involving
Selected Candidate Genes
Signature Genomics
DECIPHERCooper et al.13
Deletion Duplication Deletion Duplication
GATA4 9/21 5/29 11/11 2/8
NOTCH1 6/12 2/15 2/4 1/6
TBX1 88/324 15/172 6/15 5/22
GJA5 11/122 7/115 1/27 6/27
JAG1 1/2 1/6 2/2 1/2
CRELD1 1/12 2/13 2/10 2/3
CHRNA7 3/125 20/257 1/32 2/34
HEY1 0/2 0/3 2/2 0/1
HEY2 1/9 0/2 1/4 0/0
ATRNL1 1/3 0/8 5/7 0/0
KANSL1 8/47 1/10 2/18 0/9
All cases in the signature dataset and DECIPHER databases that involved the
candidate gene were examined; shown are the number of cases with reported
congenital cardiac defects over the total number of cases. Color coding of
genes is as described for Table 1. Note that, even for genes such as TBX1 that
have been clearly linked to congenital heart defects, chromosomal imbalances
involving those genes result in clinically recognized cardiac defects in only a
subset of cases.
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Table 3. Comparison of the Frequency of Observed Chromosomal Imbalances in Individuals with Congenital Heart Defects
(n = 1964) Compared with Controls (n = 8329)
Gene CHD Deletions Control Deletions P value CHD Duplications Control Duplications P value
AATF 3/1964 2/8329 .051 3/1964 3/8329 .09
ADAMTS1 1/1964 0/8329 .19 8/1964* 0/8329 <.0001
ARHGEF5 4/1964 0/8329 .001 1/1964 0/8329 .19
ATRNL1 0/1964 8/8329 .37 0/1964 0/8329 N/A
BMPR1A 0/1964 0/8329 N/A 0/1964 1/8329 1.00
CCSER1 0/1964 2/8329 1.00 1/1964 4/8329 1.0
CETN1 5/1964 1/8329 .001 13/1964† 6/8329 <.0001
CHCHD3 4/1964 0/8329 .001 1/1964 0/8329 .19
CHD7 2/1964 0/8329 .04 0/1964 0/8329 N/A
CHRNA7 3/1964 4/8329 .13 17/1964 58/8329 .43
CIR1 1/1964 0/8329 .19 1/1964 0/8329 .19
CNTN6 2/1964 4/8329 .32 6/1964 19/8329 .61
CREBBP 2/1964 1/8329 .10 1/1964 7/8329 1
CRELD1 1/1964 1/8329 .35 1/1964 0/8329 .19
CRKL 46/1964 1/8329 <.0001 15/1964 8/8329 <.0001
CYP2E1 4/1964 6/8329 .11 70/1964 177/8329 .0002
DACT2 1/1964 0/8329 .19 0/1964 0/8329 N/A
DOCK8 3/1964 6/8329 .39 13/1964 29/8329 .0498
DUSP22 189/1964 27/8329 <.0001 219/1964 2/8329 <.0001
EHMT1 3/1964 3/8329 .09 3/1964 0/8329 .01
ELN 14/1964 0/8329 <.0001 2/1964 0/8329 .04
ETS1 11/1964 0/8329 <.0001 1/1964 0/8329 .19
FBXO25 5/1964 4/8329 .02 2/1964 2/8329 .17
FGFR4 0/1964 0/8329 N/A 2/1964 0/8329 .04
FGFRL1 4/1964 5/8329 .07 1/1964 1/8329 .35
FOXF1 1/1964 0/8329 .19 1/1964 0/8329 .19
FSHR 1/1964 2/8329 .47 0/1964 1/8329 1.00
GATA4 7/1964 0/8329 <.0001 4/1964 0/8329 .001
GDNF 0/1964 1/8329 1.000 2/1964 3/8329 .24
GJA5 6/1964 2/8329 .001 6/1964 3/8329 .002
HAND2 5/1964 0/8329 <.0001 2/1964 0/8329 .04
HES4 5/1964 1/8329 .001 1/1964 0/8329 .19
IMMP2L 15/1964 47/8329 .3 0/1964 5/8329 1.00
KANK1 9/1964 29/8329 .47 9/1964 9/8329 .003
KANSL1 0/1964 0/8329 N/A 1/1964 0/8329 .19
LOC100506393 0/1964 2/8329 1.00 3/1964 0/8329 .01
MACROD2 10/1964 8/8329 .001 2/1964 0/8329 .04
MAPK1 2/1964 1/8329 .10 4/1964 0/8329 .001
MAPK7 0/1964 0/8329 N/A 1/1964 0/8329 .19
MEF2A 0/1964 1/8329 1.00 2/1964 1/8329 .10
MTHFR 2/1964 0/8329 .04 0/1964 0/8329 N/A
MYH11 0/1964 3/8329 1.00 4/1964 12/8329 .53
NF2 0/1964 0/8329 N/A 2/1964 0/8329 .04
NKX2-5 0/1964 0/8329 N/A 1/1964 0/8329 .19
NKX6-2 0/1964 0/8329 N/A 4/1964 2/8329 .01
NOTCH1 4/1964 3/8329 .03 1/1964 1/8329 .35
NPHP1 10/1964 36/8329 .65 23/1964 32/8329 .01
PABPC4L 8/1964 22/8329 .29 2/1964 0/8329 .04
PAK2 0/1964 0/8329 N/A 3/1964 0/8329 .01
PARK2 5/1964 24/8329 .8 8/1964 29/8329 .69
PPM1K 0/1964 0/8329 N/A 0/1964 0/8329 N/A
PRRX1 1/1964 0/8329 .19 0/1964 0/8329 N/A
RAB27A 0/1964 2/8329 1.00 0/1964 1/8329 1.00
RGPD4 0/1964 1/8329 1.00 1/1964 0/8329 .19
RUNX1 1/1964 2/8329 .47 8/1964* 1/8329 <.0001
SLC16A7 0/1964 2/8329 1.00 0/1964 1/8329 1.00
SMYD3 5/1964 1/8329 .001 2/1964 3/8329 .24
TAB2 2/1964 0/8329 .04 0/1964 0/8329 N/A
TBX1 49/1964 5/8329 <.0001 10/1964 7/8329 <.0001
TBX2 1/1964 0/8329 .19 1/1964 0/8329 .19
TBX6 2/1964 3/8329 .24 3/1964 2/8329 .051
TPPP 5/1964 4/8329 .02 4/1964 17/8329 1.0
TUBGCP5 15/1964 22/8329 .001 16/1964 36/8329 .03
ZNF595 4/1964 0/8329 .001 5/1964 3/8329 .01
ZNF804B 3/1964 0/8329 .01 1/1964 5/8329 1.0
ZNF92 14/1964 52/8329 .66 8/1964 13/8329 .04
*All with trisomy 21.
†11 out of 13 with trisomy 18.
For each candidate region, the percentage of deletions and duplications that was associated with a reported cardiac defect was recorded. To determine if the
observed difference between the CHD and control populations was statistically significant, a Wilcoxon signed-rank test was used. Statistically significant P values
are represented in bold.
ND: ALG10; AMY2A; ANTXRL; DEFB4B; GOLGA6L6; GTF2H2; LOC6464813; LRP5L; POTEB; PNPLA4; REREP3; SHOX; TOP3B.
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Locus at 1q24.2
In the databases, we identified seven individuals
with deletions involving 1q24.2. The heart defects
were variable but included VSD (3 patients),
patent foramen ovale (PFO; 2 patients), heart
defect not otherwise specified (1 patient) and
ECG abnormality (1 patient) (Table 4A). We
identified a primary critical region (CR), where
the proximal and distal boundaries were each
determined by a single case, that included nine
genes. A secondary CR, defined by allowing the
exclusion of single cases, included additional
genes. None of the genes within the primary and
secondary CRs has a known role in heart devel-
opment or the pathogenesis of congenital cardiac
defects. Although a risk calculation could not be
performed using a gene (PRRX1) within the
primary CR, the absence of chromosomal imbal-
ances involving this region in healthy controls
supports its potential role in CHD pathogenesis.
Locus at 2q31.1
Fourteen individuals with deletions (12 patients)
or duplications (2 patients) involving 2q31.1 were
identified (Table 4B). The heart defects were pri-
marily septal defects including VSD6 and ASD.3
The primary CR contained six genes with a sec-
ondary CR containing another 2. Within the
primary CR is the gene encoding for CIR1 that has
been reported to regulate the Notch signaling
pathway and to be abundantly expressed in the
heart20 and the gene encoding for the SP3 tran-
scription factor, which has been demonstrated in a
mouse model to have an important role in heart
development.21 There was one case (Wiki389) in
which the deletion did not significantly overlap
with two other deletions in the region suggesting
that (1) there is another cardiac gene located more
proximally on chromosome 2, (2) there is an effect
of the deletion on nearby genes, or (3) the dele-
tion, in that case, is not directly responsible for the
observed cardiac defect. Although a risk calcula-
tion could not be performed using a gene (CIR1)
within the primary CR, the absence of chromo-
somal imbalances involving this region in healthy
controls again supports its potential role in CHD
pathogenesis.
Locus at 15q26.3
Thirteen individuals with deletions (9 patients) or
duplications (4 patients) involving 15q26.3 were
identified (Table 4C). A broad range of cardiac
defects were noted but some less common heart
defects appeared to be overrepresented including
hypoplastic left heart syndrome (HLHS) in 3.
CoA and ventricular septal defects were also rela-
tively common. Of the genes in the primary and
secondary CRs, the gene encoding the MEF2A
transcription factor is an important candidate
based on its high level of expression in the devel-
oping heart in animal models.22
DiGeorge Syndrome Region
Previous studies have noted that mutation affect-
ing TBX1 in human patients23 or the targeted
depletion of Tbx1 in animal models24–26 can repro-
duce many of the cardiac manifestations of
DiGeorge syndrome including the development
of conotruncal-type CHDs. However, it has also
been noted that chromosomal imbalances involv-
ing chromosome 22q11 but not including TBX1
can also be associated with heart defects.27,28
Therefore, we examined the cases within the data-
bases to determine if there was evidence that
multiple genes on chromosome 22q11 might be
involved in cardiac defects. We identified 85 chro-
mosomal imbalances involving chromosome
22q11 in the database. Seventy-eight of the 85
involved at least one of three genes, TBX1, CRKL,
and MAPK1, previously determined or suspected
to have a role in human heart development and
in the pathogenesis of CHDs. Of these, seven
involved chromosomal imbalance of TBX1 alone,
35 involved TBX1 and CRKL, eight involved
CRKL alone, four involved both CRKL and
MAPK1, and 19 involved MAPK1 alone (Table 5).
Small (<300 kb) chromosomal imbalances involv-
ing chromosome 22q11 distal to MAPK1 were
noted in six patients from one database, but these
may reflect nonpathogenic rearrangements or
uncertain CNV ascertainment based on a single
testing format.
Discussion
General Approach
Identification of the causes of CHDs has proved to
be a challenging task. The underlying genetic
abnormality responsible for a cardiac defect is
known in only a very small minority of patients.
Characterization of patients with chromosomal
imbalances and associated congenital cardiac
abnormalities is an attractive approach to identi-
fying disease genes that has been successful in
identifying ELN (elastin), TBX1 and GATA4 as
genes involved in the pathogenesis of congenital
cardiac defects. Unfortunately, there are currently
a number of obstacles to this approach. Perhaps,
most importantly is the lack of a centralized,
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Table 4. Genes Contained within the Critical Regions for Three Loci
Table 4A. Critical Region on Chromosome 1q24.2 with Surrounding Genes. None of the Genes in the Primary or Secondary Critical Regions Are Strongly
Implicated in Heart Development
D 262739 D 253856 D 2572 W 1505 W 1506 W 1546 I nssv577229
DEL DEL DEL DEL DEL DEL DEL
ECG ABNL HEART VSD VSD PFO/PDA PFO VSD
TBX19 X X X X X X
XCL2 X X X X X X
XCL1 X X X X X X
DPT X X X X X X
ATP1B X X X X X X
NME7 X X X X X X
SLC19A2 X X X X X X
SELP X X X X X X
METTL18 X X X X X X X
SELL X X X X X X X
SELE X X X X X X X
KIFAP3 X X X X X X X
GORAB X X X X X X X
PRRX1 X X X X X X X
FMO3 X X X X X X X
FMO2 X X X X X X X
FMO1 X X X X X X X
PRRC2C X X X X X X
VAMP4 X X X X X X
METTL13 X X X X X X
DNM3 X X X X X X
PIGC X X X X X
FASLG X X X X X
TNSF18 X X X X X
Table 4B. Critical Region on Chromosome 2q31.1 with Surrounding Genes. SP3 and CIR1 Have Been Determined to Have a Role in Vertebrate Heart
Development in Animal Models.
W 1476 W 1475 W 1474 W 1481 W 1501 W 1502 M 12 W 389 W 77 W 78 W 79 I
nssv577738
C
9900015
D
258540
DEL DEL DEL DEL DEL DEL DEL DEL DEL DEL DEL DEL DUP DUP
VSD;
PS
ASD ASD;
PDA
VSD VSD VSD Ao MS; MR VSD ASD;
PDA
VSD;
DORV;
PS
HEART HEART HEART
PDK1 X X X X X X X X X
RAPGEF4 X X X X X X X X X
ZAK X X X X X X X X X X X X X
CDCA7 X X X X X X X X X X X X X
SP3 X X X X X X X X X X X X X
OLA1 X X X X X X X X X X X X X
CIR1 X X X X X X X X X X X X X
SCRN3 X X X X X X X X X X X X X
GPR155 X X X X X X X X X X X X X
WIPF1 X X X X X X X X X X X X X
CHRNA1 X X X X X X X X X X X
CHN1 X X X X X X X X X X X
Table 4C. Critical Region on Chromosome 15q26.3 with Surrounding Genes. MEF2A Has Been Determined to Have a Role in Vertebrate Heart
Development in Animal Models
W 1338 D 251099 D 270050 W 1314 W 1313 W 3 W 5 W 1525 D 259934 C 9902150 D 256144 D 256144 I nssv582685
DEL DEL DEL DEL DEL DEL DEL DEL DEL DUP DUP DUP DUP
HLHS;
CoA;
VSD
CoA;
VSD
VSD AVSD ASD;
PS
HLHS HLHS;
VSD
VSD VSD HEART ASD ASD HEART
NR2F2 X X X X X X X X X
ARRDC4 X X X X X X X X X X
IGF1R X X X X X X X X X X X
SYNM1 X X X X X X X X X X X
TTC23 X X X X X X X X X X X X
LRRC28 X X X X X X X X X X X X X
MEF2A X X X X X X X X X X X X X
LYSMD4 X X X X X X X X X X X X X
DNM1P X X X X X X X X X X X X X
ADAMTS17 X X X X X X X X X X X X X
CERS3 X X X X X X X X X X X X X
LINS1 X X X X X X X X X X X X X
ASB7 X X X X X X X X X X X X X
LRRK1 X X X X X X X X X X X X
PCSK6 X X X X X X X X X X X X
TARSL2 X X X X X X X X X X X
The primary critical region, where all deletions overlap, is highlighted in light gray. The secondary critical region, where all but one deletion overlap, is highlighted
in dark gray. The genes within the region and surrounding region are listed in the order that they occur on the chromosome. An X indicates that the gene is involved
in the chromosomal imbalance in that patient. The patient and the database (C: Cooper et al.,13 D: DECIPHER, I: ISCA, W: CHDWiki, and M: the University of
Michigan) or publication from which they were gathered is listed along the top row. Along the second row is the designation of whether the rearrangement was a
deletion or duplication. In the third row is the type of the cardiac defect observed if known (if unknown is listed as “HEART”). Nomenclature for heart defects is the
same as for Table 1.
Note that there is one chromosomal imbalance that was in close proximity to but did not involve the genes in the primary critical region. “Ao” indicates dilatation
of the aortic root in one patient.
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Table 5. DiGeorge Syndrome Region on Chromosome 22q11.2 with Surrounding Genes
Database Database ID CHD Chromo Type Genome Build Boundary 1 Boundary 2 Locus
I nssv579955 VSD 22 DEL hg19 17019015 20718227 TBX1
I nssv575290 HEART 22 DEL hg19 18706001 20659606 TBX1
I nssv575290 VSD 22 DEL hg19 18890271 20659606 TBX1
W 1412 VSD 22 DEL hg19 18894835 20659606 TBX1
C 9908014 HEART 22 DEL hg19 18986906 20246906 TBX1
I nssv577056 HEART 22 DEL hg19 19771355 21123068 TBX1
I nssv579962 CoA 22 DUP hg19 19074579 19928090 TBX1
I nssv1603215 HEART 22 DEL hg19 18660553 21455556 TBX1/CRKL
I nssv579970 VSD 22 DEL hg19 18661724 21561514 TBX1/CRKL
I nssv579984 HEART 22 DEL hg19 18661724 21561514 TBX1/CRKL
TM 19 TOF 22 DEL hg19 18805856 21721725 TBX1/CRKL
G 2573 TOF 22 DEL hg19 18810089 21153772 TBX1/CRKL
G 2360 TOF 22 DEL hg19 18895187 21463936 TBX1/CRKL
I nssv579993 AI 22 DEL hg19 18909032 21306115 TBX1/CRKL
I nssv1603983 HEART 22 DEL hg19 18919469 21456772 TBX1/CRKL
D 2213 HEART 22 DEL hg19 18919469 21460658 TBX1/CRKL
D 256300 VSD 22 DEL hg19 18919469 21460658 TBX1/CRKL
C 9882869 HEART 22 DEL hg19 18919469 21460658 TBX1/CRKL
C 9893576 HEART 22 DEL hg19 18919469 21460658 TBX1/CRKL
C 9883354 TOF 22 DEL hg19 18919469 21460658 TBX1/CRKL
C 9883678 HEART 22 DEL hg19 18919742 21440655 TBX1/CRKL
C 9883488 TOF 22 DEL hg19 18919742 21440655 TBX1/CRKL
C 9881580 HEART 22 DEL hg19 18919941 21440515 TBX1/CRKL
D 262934 HEART 22 DEL hg19 18919941 21440515 TBX1/CRKL
I nssv579999 TOF 22 DEL hg19 18919942 21440514 TBX1/CRKL
C 9906174 HEART 22 DEL hg19 18919942 21440514 TBX1/CRKL
C 9892257 CoA 22 DEL hg19 18919942 21440514 TBX1/CRKL
I nssv582251 ASD 22 DEL hg19 18919942 21505417 TBX1/CRKL
I nssv576304 VSD 22 DEL hg19 18919942 21505417 TBX1/CRKL
I nssv580013 HEART 22 DEL hg19 18919942 21505417 TBX1/CRKL
I nssv580012 HEART 22 DEL hg19 18919942 21505417 TBX1/CRKL
I nssv580007 CHF 22 DEL hg19 18919942 21505417 TBX1/CRKL
I nssv575367 ASD 22 DEL hg19 18919942 21561514 TBX1/CRKL
I nssv580006 HEART 22 DEL hg19 18938161 21455556 TBX1/CRKL
I nssv583020 HEART 22 DEL hg19 18938161 21455556 TBX1/CRKL
I nssv580004 PS 22 DEL hg19 18938161 21455556 TBX1/CRKL
I nssv582339 VSD 22 DEL hg19 19023824 21798755 TBX1/CRKL
I nssv580045 SAS 22 DUP hg19 18627818 21940122 TBX1/CRKL
I nssv580051 AVSD 22 DUP hg19 18660553 21455556 TBX1/CRKL
I nssv580052 HEART 22 DUP hg19 18781534 21465835 TBX1/CRKL
C 9893158 HEART 22 DUP hg19 18919942 21801604 TBX1/CRKL
D 1640 AVSD 22 DUP hg19 19573160 21461017 TBX1/CRKL
D 251689 TOF 22 DEL hg19 20330744 21465481 CRKL
D 254167 AAo 22 DEL hg19 20659547 21561514 CRKL
TM 9 HEART 22 DEL hg19 20733427 21505417 CRKL
D 768 ASD; PDA 22 DEL hg19 20734244 21460658 CRKL
D 986 VSD 22 DEL hg19 20743536 21462353 CRKL
TM 25 VSD 22 DEL hg19 20754422 21440514 CRKL
D 262483 SAS 22 DUP hg19 20763207 21461765 CRKL
I nssv580061 TOF 22 DUP hg19 20769981 21037727 CRKL
I nssv580065 VSD 22 DEL hg19 20372210 22548710 CRKL/MAPK1
W 1488 CAT 22 DEL hg19 20976969 22484320 CRKL/MAPK1
S B00BEJC ASD 22 DEL hg19 21075575 22467350 CRKL/MAPK1
I nssv575749 HEART 22 DUP hg19 21025653 22467351 CRKL/MAPK1
TM 21 CAT 22 DEL hg19 21692108 23575642 MAPK1
S B00B1CM AVSD 22 DEL hg19 21721591 22970128 MAPK1
W 98 AVSD 22 DEL hg19 21721591 22970128 MAPK1
C 9895786 VSD 22 DEL hg19 21798104 23739485 MAPK1
D 2366 HEART 22 DEL hg19 21799773 23654237 MAPK1
S B00BE7D HEART 22 DEL hg19 21808750 24643264 MAPK1
D 251833 HEART 22 DEL hg19 21811979 24616199 MAPK1
D 251833 AI 22 DEL hg19 21939922 24643109 MAPK1
D 250255 VSD; ASD; PDA 22 DEL hg19 22095272 22834113 MAPK1
D 248709 CAT 22 DEL hg19 22095272 22834113 MAPK1
I nssv580074 CAT 22 DEL hg19 22095272 22834113 MAPK1
I nssv580080 CAT 22 DEL hg19 22095272 22834113 MAPK1
TM 29 VSD; RAO 22 DEL hg19 22095272 22834113 MAPK1
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searchable, and well-annotated database of well-
phenotyped patients with clearly defined chromo-
somal imbalances. The obstacles to achieving this
goal are not insurmountable and would yield enor-
mous benefits for all patients with developmental
defects, including heart defects.
Although there are very important limitations
to the databases in their current state that restrict
the ability to make conclusions based on these
data, the database review suggested several impor-
tant considerations with regard to human heart
development and the pathogenesis of human con-
genital cardiac defects. Most importantly, the
database review reinforces the observation that
haploinsufficiency or duplication of even genes
known to be critical for heart development only
results in heart defects in a subset of cases. For
instance, haploinsufficiency of TBX1 led to clini-
cally significant heart defects in 27% of patients in
the Signature dataset and 40% in the DECIPHER
database. The Signature dataset may have a lower
ascertainment and reporting bias but also may
under-report or under-detect heart defects. The
DECIPHER database is more prone to ascertain-
ment and reporting bias, which may inflate the
estimated frequency of heart defects in patients
with 22q11 deletions. Clearly, other factors are
involved that help determine whether an indi-
vidual with a genetic predisposition, such as TBX1
haploinsufficiency, manifests a significant cardiac
abnormality.
At least some of the clinical variability in cases
of chromosome 22q11 deletion may be related to
the extent of the deletion. In the database, as has
been noted in previous studies, most commonly,
cases (30 out of 85 reported) with a CHD and a
chromosomal imbalance affecting chromosome
22q11 had an approximately 3 Mb deletion, which
included both the TBX1 and CRKL genes. A
smaller 1.5 Mb deletion involving TBX1 but not
CRKL was noted in six patients in the database.
The smaller deletion has been previously noted to
account for DiGeorge syndrome in approximately
7% of cases and the larger deletion in 88%.29,30
The smaller deletion has been noted to be suffi-
cient to produce the full DiGeorge syndrome
phenotype31 including conotruncal heart defects,32
but there has been noted to be an important dif-
ference in the rate at which the 1.5 Mb deletion
and the 3 Mb deletion are passed to offspring.33
The reduced rate of transmission of the larger
deletion may indicate that the early developmental
defects are more penetrant or more severe in the
patients with the larger deletion. In our database,
the patients with the smaller 1.5 Mb deletion had
ventricular septal defects and unspecified heart
abnormalities while those with the larger 3 Mb
deletion, encompassing both TBX1 and CRKL,
demonstrated a range of heart defects including
TOF (six cases), VSD (three cases), and pulmo-
nary stenosis (one case). Conotruncal heart defects
including truncus arteriosus (CAT) and TOF were
Table 5. Continued
Database Database ID CHD Chromo Type Genome Build Boundary 1 Boundary 2 Locus
C 9890170 BAV 22 DEL hg19 22095272 22834113 MAPK1
W 21 CAT 22 DEL hg19 22095272 22834113 MAPK1
W 18 CAT 22 DEL hg19 22115848 23696229 MAPK1
W 24 CAT 22 DEL hg19 22115848 23696229 MAPK1
W 23 VSD 22 DEL hg19 22115848 23696229 MAPK1
W 22 TA 22 DUP hg19 21934556 22381654 MAPK1
W 26 CAT 22 DEL hg19 19031487 23071636 TBX1/CRKL/MAPK1
W 28 VSD 22 DUP hg19 17397498 51178264 TBX1/CRKL/MAPK1
W 1003 VSD 22 DUP hg19 17397498 51178264 TBX1/CRKL/MAPK1
W 27 DORV; SI 22 DUP hg19 18546349 22336469 TBX1/CRKL/MAPK1
S B00BDZ8 ECG 22 DUP hg19 19174809 22264418 TBX1/CRKL/MAPK1
S B00B0MB CAT 22 DUP hg19 19771355 19771891
S B00B15I TA; TGA 22 DUP hg19 22308883 22573637 TOP3B
S B00BQP9 TOF 22 DUP hg19 22311326 22573637 TOP3B
W 29 AS 22 DEL hg19 22312383 22573637 TOP3B
W 25 TOF 22 DEL hg19 22315312 22573637 TOP3B
S B009FPG BAV 22 DUP hg19 22315312 22571854 TOP3B
S B00B0D1 TOF 22 DUP hg19 22315312 22573637 TOP3B
Data presented for each case includes the database source, the case ID number, the type of heart defect noted (CHD), the chromosome affected by the deletion
or duplication (Chrom), the type of chromosomal imbalance (deletion [DEL] or duplication [DUP]) identification, the genome build of the annotated sequence
involved (all hg19), and the approximate proximal (Boundary 1) and distal (Boundary 2) boundaries of the observed imbalance, and the candidate gene or genes
involved in the imbalance (Locus). The chromosomal imbalances were divided into those involving just TBX1, TBX1 and CRKL, CRKL only, CRKL and MAPK1,
MAPK1 only, and all three. Shading indicates involvement of more that one candidate gene. In six cases, a small chromosomal rearrangement occurred between
CRKL and MAPK1 but did not involve either gene. All of those cases did involve imbalance of the gene TOP3B, a gene not known to be involved in heart
development. Only one chromosomal imbalance of 22q11 did not involve one of those four loci. Nomenclature for heart defects is the same as for Table 1. Sources
listed include the following databases and publications: Cooper et al.13 (C), DECIPHER (D), ISCA (I), CHDWiki (W), Tomita-Mitchell et al.12 (TM), Greenway et al.11
(G), Soemedi et al.14 (S), and the University of Michigan (M).
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noted in cases involving deletions distal to the
1.5 Mb smaller DiGeorge syndrome deletion,
including deletions involving (1) the distal part of
the 3 Mb deletion region (and including CRKL)
and/or (2) deletion of more distal 22q11 including
MAPK1. The ability of 22q11 deletions that do
not involve TBX1 to result in conotruncal cardiac
defects has been previously noted in cases involv-
ing the loss of both CRKL and MAPK1.28 There-
fore, the concurrent loss of 2 or more genes
involved in cardiac development as occurs with the
simultaneous loss of TBX1 and CRKL in the larger
and more common 3 Mb DiGeorge syndrome
deletion or with the less common simultaneous
loss of CRKL and MAPK1 may enhance the pen-
etrance of cardiac defects in patients with 22q11
deletions. This is supported by knockout studies in
mice that demonstrated a higher penetrance and
severity of cardiac defects in mice haplosufficient
for both TBX1 and CRKL compared to mice hap-
losufficient for either individually.34
CHD penetrance may also vary by disease
locus. Chromosomal imbalances involving
GATA4 and NKX2-5 are rare but, when they
occur, seem to be associated with a high fre-
quency of clinically significant cardiac defects.
Few other loci appear to have comparable pen-
etrance with regard to haploinsufficiency and the
incidence of heart defects. However, disease
genes that reside in regions that are relatively
stable (i.e., very rarely involved in chromosomal
imbalances) or in regions where chromosomal
imbalances are associated with markedly reduced
viability may be difficult to detect using this
approach.
The generated composite database of each indi-
vidual case (Supporting Information Table S1) will
provide a useful starting point for the identifica-
tion of novel genomic regions potentially involved
in human heart development and the pathogenesis
of congenital cardiac defects. Identification of
such regions will facilitate the interpretation of
genome-wide sequencing data, in the search for
the genetic determinants of congenital cardiac
defects. As cases are added to the database there
may be further refinement of the region deter-
mined to be critical for heart development.
Examples of how deletion/duplication mapping
may be used to restrict candidate regions and iden-
tify potential candidate genes are described below.
Locus at 1q24.2
Deletions of 1q24 are relatively uncommon.
There was a report of seven patients with deletion
of 1q24.3-1q25 that overlaps minimally with the
CHD CR defined in this study.35 Cardiac defects
were not noted to be an important feature of their
observed phenotype. As noted above, none of the
genes within the primary and secondary CRs has a
known role in heart development or the pathogen-
esis of congenital cardiac defects. Of the genes
in the primary CR, GORAB, and PRRX1 are
expressed in the heart, but loss of function in
human patients or in animal models is not associ-
ated with heart defects.36–38 Similarly, in the sec-
ondary CR, VAMP4, and DNM3 are expressed the
heart, but no role in cardiac development has been
identified. In addition, there are a number of
miRNAs that have been identified within the CRs
at this locus. Most interesting is mir-214, which
is encoded within the DNM3 locus, is highly
expressed in the heart and promotes myogenic
differentiation.39
Locus at 2q31.1
Duplication of chromosome 2q31.1 has been noted
in a 3 generation familywithmesomelic dysplasia,40
but deletions involving 2q31.1 are relatively
uncommon.41 The predominant cardiac lesions in
patients with 2q31.1 deletions that have been
recorded in the databases are defects in cardiac
septation resulting in ASDs and VSDs. Within the
primary CR on chromosome 2q31 is CBF1-
interacting co-repressor (CIR1) (Table 4B). CBF1
(or RBPJ) is a transcriptional repressor whose
activity is de-repressed by binding to the Notch
intracellular domain, making it a key target in
Notch-mediated transcriptional activation. CIR1’s
high level of expression in the heart and interaction
with a signaling pathway critical for heart develop-
mentmakeCIR1 a likely candidate for the observed
cardiac defects in these patients.20 Other genes
within the primary and secondary CRs that are
expressed in the heart include PDK1 (pyruvate
dehydrogenase kinase), transcription factor SP3,
and ZAK. ZAK encodes a kinase that activates
MAPK1,42 another kinase implicated in the patho-
genesis of congenital cardiac defects,28 and SP3
encodes for a transcription factor that is required
for normal heart development in the mouse.21
Locus at 15q26.3
A recurring deletion of chromosome 15q26.3
described by Rump et al.43 was noted to be respon-
sible for a distinct clinical phenotype that had been
named Drayer syndrome. Common features
include micrognathia, developmental delay, skel-
etal anomalies and growth failure. As noted above,
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MEF2A, a transcription factor strongly expressed
in smooth muscle throughout the body, including
the smooth muscle of the developing heart tube, is
a strong candidate for the heart defects associated
with 15q26 deletions as has been previously pro-
posed.44 Another candidate within the region is
ADAMTS17, which is expressed in the developing
heart.45 However, deleterious mutations of
ADAMTS17 in human patients cause ocular and
ophthalmologic abnormalities but have not led to
the development of CHDs.45
It is important to note that haploinsufficiency of
this region did lead to heart defects with related
etiologies, as two of the more commonly noted
lesions with these deletions, HLHS and CoA, can
occur together in families and are often defined as
closely related left-sided obstructive lesions.46
Therefore, a gene or genes within this region may
be an important candidate(s) to consider when
evaluating patients with left-sided obstructive
lesions including HLHS.
DiGeorge Region
In several regions, nonoverlapping chromosomal
imbalances are associated with cardiac defects, sug-
gesting that more than one gene in the region
participates in heart development. Given that (1)
the “penetrance” of the cardiac phenotype in
response to a chromosomal imbalance is variable
and can be quite low even for imbalances involving
a gene known to participate in heart development
and (2) the incidence of heart defects in the general
population is high enough that not all defects can
be assumed to be “caused” by the observed imbal-
ance, it can be very difficult to determine the
precise extent of the candidate regions and the
number of heart development genes involved. One
region that may contain more than a single gene
involved in heart development is chromosome
22q11, which includes the DiGeorge syndrome
CR. As noted above, TBX1, which encodes for a
T-box cardiac transcription factor, is within the CR
and has been demonstrated in animal models to
have an important role in heart development.23,26,47
However, nonoverlapping chromosomal imbal-
ances associated with heart defects have suggested
the possibility of two additional 22q11 genes
involved in heart development, and several lines of
evidence support the potential involvement of the
CRKL andMAPK1 genes.28,48,49 Review of the cases
in the databases support the existence of at least
three genes on chromosome 22q11 that contribute
to cardiac development.
Limitations
As noted above, there are a number of important
limitations to this study. The databases and pub-
lications included in this analysis do not share a
common genotyping platform, do not have a
consistent approach to phenotyping or pheno-
type reporting and are entirely voluntary. We
have included a supplemental table that contains
some basic information regarding each of the
reported cases (Supporting Information
Table S1). We recognize that our list of 79 loci
involved in five or more rearrangements is
incomplete and that there will be many instances
where (1) multiple candidate genes have been
encompassed by a single locus; (2) only a single
candidate gene is present where there are several
closely spaced candidate regions; (3) “false” loci
have been created by database errors, random
chance and genomic instability; and (4) “true”
loci have been missed due to genomic stability
(leading to very few cases of chromosomal imbal-
ance for evaluation) and/or reduced viability of
affected embryos. The list is meant to be a pre-
liminary effort to consolidate what is known to
date and it will need to be refined or replaced as
case reporting becomes more standardized. The
supplementary table will serve as a platform for
identifying new candidate loci as additional cases
are added to the database and will help to further
refine existing loci.
Summary
Despite the limitations of this study, the database
analysis demonstrates the potential value of this
approach to restrict regions of interest for genes
involved in developmental disorders including
congenital cardiac defects. The low penetrance for
observable cardiac defects associated with most
chromosomal imbalances, the infrequent occur-
rence of chromosomal abnormalities in most
genomic regions, and the relatively common
occurrence of some types of cardiac defects (such
as ASDs and VSDs) in the general population will
make it difficult to define CRs based on a single
patient or small cohorts. Therefore, there will be
tremendous value in establishing standardized
processes for reporting observed chromosomal
imbalances and associated clinical phenotypes.
The refined map of loci involved in human cardiac
development will be essential as genome-wide
sequencing approaches become more prevalent in
the search for the genetic determinants of con-
genital cardiac defects.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Table S1. All 1762 cases collected for this study are pre-
sented. Data presented for each case includes the database
source, the case ID number, the type of heart defect noted
(CHD), the chromosome affected by the deletion or dupli-
cation (Chrom), the type of chromosomal imbalance (dele-
tion [DEL] or duplication [DUP]) identification, the
genome build of the annotated sequence involved (all
hg19), and the approximate proximal (Boundary 1) and
distal (Boundary 2) boundaries of the observed imbalance,
and the candidate gene or genes involved in the imbalance
(Locus). Loci highlighted in red were affected in 5 or more
patients with heart defects. For each case, the chromosome
(Chrom) and approximate genetic location (Genome Ref-
erence Consortium Human Build 37 [GRCh37/hg19]), a
gene within the minimal region of overlap, the observed
heart defects and the source of the case (database or pub-
lication) are shown. The gene listed is not the only one
within the critical region but is a representative one and, if
one is present, will be the gene within the interval deter-
mined to have a role in heart development. Identification
of all genes in the primary and secondary critical regions
would require further mapping as noted in Tables 4 and 5.
Heart defects listed include coarctation of the aorta (CoA),
interrupted aortic arch (IAA), hypoplastic left heart syn-
drome (HLHS), atrial and ventricular septal defects (ASDs
and VSDs), atrioventricular septal defect (AVSD), tetral-
ogy of Fallot (TOF), double outlet right ventricle
(DORV), bicuspid aortic valve (BAV), truncus arteriosus
(CAT), situs inversus (SI), heterotaxy (HET), supravalvar
aortic and pulmonary stenosis (SVAS and SVPS), aortic
stenosis or insufficiency (AS or AI), pulmonary stenosis or
insufficiency (PS or PI), tricuspid stenosis or regurgitation
(TS or TR), mitral stenosis or regurgitation (MS or MR),
total or partial anomalous venous return (TAPVR or
PAPVR), tricuspid atresia (TA), pulmonary atresia (PA),
patent ductus arteriosus (PDA), left or bilateral superior
vena cava (LSVC or BSVC), cardiomyopathy and left ven-
tricular noncompaction (CM and LVNC), and Ebstein’s
anomaly (EBS). If the heart defect wasn’t described then
“HEART” is listed. Sources listed include the following
databases and publications: Cooper et al.13 (C), DECI-
PHER (D), ISCA (I), CHDWiki (W), Tomita-Mitchell
et al.12 (TM), Greenway et al.11 (G), Soemedi et al.14 (S),
and the University of Michigan (M).
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